An ingestible self-orienting system for oral delivery of macromolecules

Alex Abramson(Massachusetts Institute of Technology), Ester Caffarel–Salvador(Massachusetts Institute of Technology), Minsoo Khang(Massachusetts Institute of Technology), David Dellal(Massachusetts Institute of Technology), David M. Silverstein(Massachusetts Institute of Technology), Yuan Gao(Massachusetts Institute of Technology), Morten Revsgaard Frederiksen(Novo Nordisk (Denmark)), Andreas Vegge(Novo Nordisk (Denmark)), František Hubálek(Novo Nordisk (Denmark)), Jorrit J. Water(Novo Nordisk (Denmark)), Anders V. Friderichsen(Novo Nordisk (Denmark)), Johannes Josef Fels(Novo Nordisk (Denmark)), Rikke Kaae Kirk(Novo Nordisk (Denmark)), Cody Cleveland(Novo Nordisk (Denmark)), Joy Collins(Massachusetts Institute of Technology), Siddartha Tamang(Massachusetts Institute of Technology), Alison Hayward(Massachusetts Institute of Technology), Tomas Landh(Novo Nordisk (Denmark)), Stephen T. Buckley(Novo Nordisk (Denmark)), Niclas Roxhed(Massachusetts Institute of Technology), Ulrik L. Rahbek(Novo Nordisk (Denmark)), Róbert Langer(Massachusetts Institute of Technology), Giovanni Traverso(Brigham and Women's Hospital)
Science
February 8, 2019
Cited by 428Open Access
Full Text

Abstract

Biomacromolecules have transformed our capacity to effectively treat diseases; however, their rapid degradation and poor absorption in the gastrointestinal (GI) tract generally limit their administration to parenteral routes. An oral biologic delivery system must aid in both localization and permeation to achieve systemic drug uptake. Inspired by the leopard tortoise's ability to passively reorient, we developed an ingestible self-orienting millimeter-scale applicator (SOMA) that autonomously positions itself to engage with GI tissue. It then deploys milliposts fabricated from active pharmaceutical ingredients directly through the gastric mucosa while avoiding perforation. We conducted in vivo studies in rats and swine that support the applicator's safety and, using insulin as a model drug, demonstrated that the SOMA delivers active pharmaceutical ingredient plasma levels comparable to those achieved with subcutaneous millipost administration.


Related Papers

No related papers found

Powered by citation graph analysis